Osteoporosis: trends in epidemiology, pathogenesis and treatment

[1]  H. Genant,et al.  Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[2]  R. Epstein,et al.  Pre-existing fractures and bone mass predict vertebral fracture incidence in women. , 1991, Annals of internal medicine.

[3]  C. Cooper,et al.  Incidence of clinically diagnosed vertebral fractures: A population‐based study in rochester, minnesota, 1985‐1989 , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  François Duboeuf,et al.  Vitamin D3 and Calcium to Prevent Hip Fractures in Elderly Women , 1992 .

[5]  Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy , 1993 .

[6]  I. Reid,et al.  Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. , 1995, The American journal of medicine.

[7]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[8]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[9]  O. Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .

[10]  Roberto Pacifici,et al.  Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  G. Mundy,et al.  Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β , 1996, Nature Medicine.

[12]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[13]  Lynn Wei,et al.  Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. , 1997, The Journal of clinical investigation.

[14]  O Johnell,et al.  The socioeconomic burden of fractures: today and in the 21st century. , 1997, The American journal of medicine.

[15]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[16]  C. Cooper,et al.  Vertebral Fractures Predict Subsequent Fractures , 1999, Osteoporosis International.

[17]  Jane A. Cauley,et al.  Vitamin D receptor gene polymorphisms and the risk of fractures in older women , 1999 .

[18]  J. Eisman,et al.  Mortality after all major types of osteoporotic fracture in men and women: an observational study , 1999, The Lancet.

[19]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[20]  S. Cummings,et al.  What PROOF proves about calcitonin and clinical trials. , 2000, The American journal of medicine.

[21]  P. Delmas,et al.  Biochemical Markers of Bone Turnover, Endogenous Hormones and the Risk of Fractures in Postmenopausal Women: The OFELY Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  T. Abbott,et al.  Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  D. Kiel,et al.  Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis , 2000, Aging.

[24]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[25]  R. Pacifici,et al.  Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. , 2000, The Journal of clinical investigation.

[26]  R. Rizzoli,et al.  Gain in bone mineral mass in prepubertal girls 3–5 years after discontinuation of calcium supplementation: a follow-up study , 2001, The Lancet.

[27]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[28]  Miikka Vikkula,et al.  LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.

[29]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[30]  J. Ioannidis,et al.  Association of Collagen Iα 1 Sp1 Polymorphism with the Risk of Prevalent Fractures: A Meta‐Analysis , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  C. Cooper,et al.  Epidemiology of fractures in England and Wales. , 2001, Bone.

[32]  R M Aspden,et al.  A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. , 2001, The Journal of clinical investigation.

[33]  O. Johnell,et al.  Biochemical Indices of Bone Turnover and the Assessment of Fracture Probability , 2002, Osteoporosis International.

[34]  G. Guyatt,et al.  IV. Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis , 2002 .

[35]  C. Cooper,et al.  Prenatal and childhood influences on osteoporosis. , 2002, Best practice & research. Clinical endocrinology & metabolism.

[36]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[37]  Gordon Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. , 2002, Endocrine reviews.

[38]  Jacques P. Brown,et al.  The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis , 2002, Calcified Tissue International.

[39]  T. Spector,et al.  Gender Differences in the Genetic Factors Responsible for Variation in Bone Density and Ultrasound , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  J Dequeker,et al.  Incidence of Vertebral Fracture in Europe: Results From the European Prospective Osteoporosis Study (EPOS) , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  B. L. Riggs,et al.  Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures Without Commensurate Increases in Bone Density , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  J. Pfeilschifter,et al.  Changes in proinflammatory cytokine activity after menopause. , 2002, Endocrine reviews.

[43]  O. Johnell,et al.  Uncertain Future of Trials in Osteoporosis , 2002, Osteoporosis International.

[44]  J. Reginster,et al.  Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. , 2002, The Journal of clinical endocrinology and metabolism.

[45]  Mark L. Johnson,et al.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. , 2002, American journal of human genetics.

[46]  Richard P Lifton,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[47]  O. Johnell,et al.  Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[48]  S. Cummings,et al.  Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.

[49]  Jacques P. Brown,et al.  Intravenous zoledronic acid in postmenopausal women with low bone mineral density. , 2002, The New England journal of medicine.

[50]  R. Doll,et al.  Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial , 2003, BMJ : British Medical Journal.

[51]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[52]  J. Compston,et al.  The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. , 2003, Bone.

[53]  H. Genant,et al.  Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. , 2003, Bone.

[54]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[55]  C. Cooper,et al.  Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. , 2003, Bone.

[56]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[57]  B. Ettinger,et al.  Early discontinuation of treatment for osteoporosis. , 2003, The American journal of medicine.

[58]  B. Ettinger,et al.  Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[59]  E. Barrett-Connor,et al.  Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[60]  A. Uitterlinden,et al.  Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. , 2004, American journal of human genetics.

[61]  A. Uitterlinden,et al.  Influence of LRP5 Polymorphisms on Normal Variation in BMD , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[62]  T. J. Rosenberg,et al.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. , 2004, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[63]  Niklas Zethraeus,et al.  Assessment of fracture risk , 2005, Osteoporosis International.

[64]  O Johnell,et al.  A meta-analysis of previous fracture and subsequent fracture risk. , 2004, Bone.

[65]  C. Christiansen,et al.  Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[66]  Krista F. Huybrechts,et al.  The impact of compliance with osteoporosis therapy on fracture rates in actual practice , 2004, Osteoporosis International.

[67]  T. Spector,et al.  Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.

[68]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[69]  P. Geusens,et al.  Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAX® versus EVISTA®Comparison Trial) International 1 , 2004, Journal of internal medicine.

[70]  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004 .

[71]  D. Ovcharenko,et al.  Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. , 2005, Genome research.

[72]  L. Palermo,et al.  One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. , 2005, The New England journal of medicine.

[73]  F. Islam,et al.  LRP5 gene polymorphisms predict bone mass and incident fractures in elderly Australian women. , 2005, Bone.

[74]  Xi He,et al.  SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor* , 2005, Journal of Biological Chemistry.

[75]  S. Cummings,et al.  Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[76]  Bess Dawson-Hughes,et al.  Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. , 2005, JAMA.

[77]  Peng Liu,et al.  Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling* , 2005, Journal of Biological Chemistry.

[78]  C. Cooper,et al.  Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial , 2005, The Lancet.

[79]  R. Lindsay,et al.  Daily and cyclic parathyroid hormone in women receiving alendronate. , 2005, The New England journal of medicine.

[80]  M. Hochberg,et al.  Treatment With Once‐Weekly Alendronate 70 mg Compared With Once‐Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double‐Blind Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[81]  P. Kannus,et al.  Prevention of falls and consequent injuries in elderly people , 2005, The Lancet.

[82]  D. Bauer,et al.  Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. , 2005, Endocrine reviews.

[83]  J. Reginster,et al.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. , 2005, The Journal of clinical endocrinology and metabolism.

[84]  Dieter Felsenberg,et al.  Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1‐Year Results From the MOBILE Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[85]  Mark C. Peterson,et al.  Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2006 .

[86]  J. Manson,et al.  Calcium plus vitamin D supplementation and the risk of fractures. , 2006, The New England journal of medicine.

[87]  G. H. Nancollas,et al.  Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. , 2006, Bone.

[88]  E. Salpeter,et al.  Mortality associated with hormone replacement therapy in younger and older women , 2004, Journal of General Internal Medicine.